A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial
Most Cited Paper
in Mycobacterium research and diagnosis
18 Months Post-Publication
Class of 2026
“A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
Ganfeborole · Ganfeborole · benzoxaborole · leucyl-tRNA synthetase · Mycobacterium tuberculosis · rifampicin-susceptible tuberculosis · early bactericidal activity · pulmonary tuberculosis · sputum-derived colony-forming units · Rifafour e-275 · 18F-fluorodeoxyglucose positron emission tomography · computed tomography · tuberculosis lesion types · Whole blood transcriptional response · neutrophil-dominated transcriptional modules · phase 2a trial · first-in-class inhibitor
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Mycobacterium research and diagnosis Papers, Class of 2026. https://pri.pepkio.com/top-papers/mycobacterium-research-and-diagnosis/2026. Accessed 2026-07-29. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459